Tang GH, Ni RZ, Xiao MB, Jiang F, Chen JH, Huang H. Clinical significance of PD-ECGF expression in human pancreatic carcinoma.
Shijie Huaren Xiaohua Zazhi 2010;
18:143-148. [DOI:
10.11569/wcjd.v18.i2.143]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To investigate the expression of platelet-derived endothelial cell growth factor (PD-ECGF) in human pancreatic carcinoma and evaluate its clinical significance.
METHODS: Immunohistochemistry was used to detect the expression of PD-ECGF in 36 paraffin-embedded pancreatic carcinoma specimens, 21 tumor-adjacent normal tissue specimens, and 60 cancerous specimens derived from other tissues (stomach, colon, esophagus, liver, lung and breast; 10 specimens each). The expression of PD-ECGF in different tissues was compared. The correlation between PD-ECGF expression and clinical parameters in pancreatic carcinoma was analyzed.
RESULTS: The positive rate of PD-ECGF in pancreatic carcinoma was higher than that in tumor-adjacent normal tissue (88.9% vs 28.6%, P < 0.01). The positive rates of PD-ECGF in cancerous colon, liver, breast, esophagus, stomach and lung tissues were 60%, 70%, 80%, 90%, 90% and 80%, respectively. The positive rate of PD-ECGF in pancreatic carcinoma at stage II-IV was higher than that at stage I (100% vs 75%, P < 0.05).
CONCLUSION: PD-ECGF is an organ-unspecific tumor-associated protein that may be associated with the progression of pancreatic carcinoma.
Collapse